<DOC>
	<DOCNO>NCT01687439</DOCNO>
	<brief_summary>Primary objective : functional image quantitative image detection effect Endostar combine chemotherapy radiotherapy Non-small Cell Lung Cancer ( NSCLC ) . Secondary objective : To evaluate 1 ) role Endostar regulate tumor vessel normalize microenvironment ; 2 ) Toxicity Endostar combine chemotherapy .</brief_summary>
	<brief_title>Effect Endostar Combined With Chemotherapy Radiotherapy Blood Vessels Microenvironment Tumor Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically cytologically proven inoperable stage IIIbIV NSCLC ECOG PS 01 Life expectancy &gt; 3 month Adequate blood function : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L , platelet count ≥ 100 x 109/L , hemoglobin ≥ 9 g / dL Adequate liver function : total bilirubin &lt; 1.5 time upper limit normal ( ULN ) ; AST ALT &lt; 2.5 time ULN patient without liver metastasis , &lt; 5 time ULN patient liver metastasis Adequate renal function : serum creatinine ≤ 1.25 time ULN calculate creatinine clearance ≥ 50 mL / min urinary protein &lt; 2+ . In patient baseline urinary protein ≥ 2+ , 24 hour urine collect 24 hour urine protein ≤ 1g International normalize ratio ( INR ) ≤ 1.5 prothrombin time ( PT ) ≤ 1.5 time ULN within 7 day enrollment Written inform consent Evidence bleed diathesis coagulopathy History hemoptysis , define bright red blood half teaspoon 3 month enrollment Previously receive chemotherapy radiotherapy biological target therapy Uncontrolled hypertension ( systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mm Hg ) Clinically significant ( ie , active ) cardiovascular disease , cerebrovascular accident ( within 6 month initiate treatment ) , myocardial infarction ( within 6 month initiate treatment ) , unstable angina , congestive heart failure ( New York Heart Association class ≥Grade II ) , serious arrhythmia need medication study may affect study control drug Unhealed wound , active peptic ulcer fracture Gastrointestinal fistula , gastrointestinal perforation intraabdominal abscess within 6 month enrollment Women intact uterus ( menopause two year exclude ) unwilling take effective nonhormonal contraception ( IUD , spermicide barrier birth control device sterilization ) study . Male unwilling take effective contraceptive measure study Participated clinical trial within 28 day initiation treatment . Allergic study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>